REGENXBIO Inc. (RGNX) Insider Stephen Yoo Sells 32,658 Shares
REGENXBIO Inc. (NASDAQ:RGNX) insider Stephen Yoo sold 32,658 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $25.00, for a total value of $816,450.00. Following the completion of the transaction, the insider now directly owns 31,803 shares in the company, valued at $795,075. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of REGENXBIO Inc. (NASDAQ RGNX) traded up 3.63% during mid-day trading on Friday, hitting $25.70. The stock had a trading volume of 269,332 shares. The firm has a 50 day moving average of $20.47 and a 200-day moving average of $19.80. The stock’s market cap is $793.98 million. REGENXBIO Inc. has a one year low of $12.82 and a one year high of $25.85.
REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. The company had revenue of $6.56 million during the quarter. Equities research analysts expect that REGENXBIO Inc. will post ($2.87) earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Redmile Group LLC bought a new stake in shares of REGENXBIO during the first quarter worth $24,494,000. Victory Capital Management Inc. increased its position in shares of REGENXBIO by 30.9% during the first quarter. Victory Capital Management Inc. now owns 46,969 shares of the biotechnology company’s stock worth $907,000 after acquiring an additional 11,079 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of REGENXBIO during the first quarter worth $272,000. Vanguard Group Inc. increased its position in shares of REGENXBIO by 23.2% during the first quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock worth $18,942,000 after acquiring an additional 184,700 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of REGENXBIO by 6.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 73,724 shares of the biotechnology company’s stock worth $1,423,000 after acquiring an additional 4,275 shares in the last quarter. 73.23% of the stock is owned by institutional investors.
A number of research analysts recently commented on the company. Chardan Capital reissued a “buy” rating and issued a $75.00 price target (up from $55.00) on shares of REGENXBIO in a report on Tuesday. Zacks Investment Research cut REGENXBIO from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Evercore ISI assumed coverage on REGENXBIO in a report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price objective on the stock. Finally, BidaskClub raised REGENXBIO from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $37.00.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Stock Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related stocks with our FREE daily email newsletter.